Semaglutide Research: What 5,123 Studies Show (2026) | RetatrutideCompare

Semaglutide — 5,123 studies indexed on PubMed. Long-acting GLP-1 receptor agonist. Glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, central satiety signaling. Half-life: ~165 hours (~7 days). FDA status: FDA-approved (Ozempic 2017, Rybelsus 2019, Wegovy 2021).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Semaglutide?

There are approximately 5,123 studies indexed on PubMed that mention Semaglutide (Ozempic, Wegovy), based on a search last updated 2026-06-18.

Is Semaglutide FDA-approved?

FDA status: FDA-approved (Ozempic 2017, Rybelsus 2019, Wegovy 2021).

How does Semaglutide work?

Long-acting GLP-1 receptor agonist. Glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, central satiety signaling.

Long-acting GLP-1 receptor agonist. Glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, central satiety signaling.

Reference facts

Also known as
Ozempic, Wegovy, Rybelsus
Category
GLP-1 & Metabolic
Mechanism of action
Long-acting GLP-1 receptor agonist. Glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, central satiety signaling.
Targets
GLP-1R
Indications under research or approved
Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction (T2D + CVD)
Regulatory status (reference entry)
FDA-approved (Ozempic 2017, Rybelsus 2019, Wegovy 2021)
Half-life
~165 hours (~7 days)
Sequence
HXEGTFTSDVSSYLEGQAAKEFIAWLVRGRG
Sequence notes
31-residue GLP-1 analog. Aib at position 2 (X), C18 fatty diacid linker at Lys26, Arg substitution at position 34.
Molecular weight (Da)
4114
PDB accession
4ZGM
Originator / sponsor
Novo Nordisk
First reported
2012
Origin
Developed by Novo Nordisk by extending the half-life of Liraglutide via a longer fatty diacid linker.

Primary References

Explore research articles about Semaglutide

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.